Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Campbell

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Future Oncology (London, England)|September 6, 2017
Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndzAli McBride, Sanjeev Balu, Kim Campbell, et al.
Journal of Medical Economics|July 20, 2017
Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaAli McBride, Kim Campbell, Mohan Bikkina, et al.
Journal of Medical Economics|March 22, 2018
Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaAli McBride, Kim Campbell, Mohan Bikkina, et al.
Journal of Medical Economics|April 24, 2020
Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastimAli McBride, Weijia Wang, Kim Campbell, et al.
Journal of Managed Care & Specialty Pharmacy|April 30, 2021
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysisAli McBride, Kim Campbell, Edward Li, et al.
Journal of Child Neurology|June 29, 2010
Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for managementRichard T Moxley, Shree Pandya, Emma Ciafaloni, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|February 1, 2023
Directive clinique n<sup>o</sup> 432a : Maturation cervicale et déclenchement artificiel du travail - Information généraleDebbie Robinson, Kim Campbell, Sebastian R Hobson, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|February 1, 2023
Guideline No. 432c: Induction of LabourDebbie Robinson, Kim Campbell, Sebastian R Hobson, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|February 1, 2023
Directive clinique n<sup>o</sup> 432c : Déclenchement artificiel du travailDebbie Robinson, Kim Campbell, Sebastian R Hobson, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|February 1, 2023
Directive clinique n<sup>o</sup> 432b : Maturation cervicaleDebbie Robinson, Kim Campbell, Sebastian R Hobson, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Future Oncology (London, England)|September 6, 2017
Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndzAli McBride, Sanjeev Balu, Kim Campbell, et al.
Journal of Medical Economics|July 20, 2017
Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaAli McBride, Kim Campbell, Mohan Bikkina, et al.
Journal of Medical Economics|March 22, 2018
Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaAli McBride, Kim Campbell, Mohan Bikkina, et al.
Journal of Medical Economics|April 24, 2020
Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastimAli McBride, Weijia Wang, Kim Campbell, et al.
Journal of Managed Care & Specialty Pharmacy|April 30, 2021
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysisAli McBride, Kim Campbell, Edward Li, et al.
Journal of Child Neurology|June 29, 2010
Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for managementRichard T Moxley, Shree Pandya, Emma Ciafaloni, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|February 1, 2023
Directive clinique n<sup>o</sup> 432a : Maturation cervicale et déclenchement artificiel du travail - Information généraleDebbie Robinson, Kim Campbell, Sebastian R Hobson, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|February 1, 2023
Guideline No. 432c: Induction of LabourDebbie Robinson, Kim Campbell, Sebastian R Hobson, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|February 1, 2023
Directive clinique n<sup>o</sup> 432c : Déclenchement artificiel du travailDebbie Robinson, Kim Campbell, Sebastian R Hobson, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|February 1, 2023
Directive clinique n<sup>o</sup> 432b : Maturation cervicaleDebbie Robinson, Kim Campbell, Sebastian R Hobson, et al.
Pageof 7